Clinical trials: Chemotherapeutic Agent Toxicity
Pancreas Cancer, Colorectal Cancer
The Relationship Between Fat Free Mass and Toxicity of Cytostatics in Cancer Patients
An observational study of the relationship between fat free mass and toxicity of cytostatics in cancer patients, at the department of Clinical Oncology at Zealand University Hospital, Roskilde, Denmark.
- Trial name
- NCT04528745
- Testing
- Bio Impedance Spectroscopy (BIS)
- Where
- Denmark
- Volunteers
- 52 people
- Sponsor
- University of Copenhagen
Chemotherapeutic Agent Toxicity, Colorectal Cancer
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
RATIONALE: Studying samples of blood in the laboratory from patients receiving oxaliplatin for cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to neurotoxicity.
- Conditions
- Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neurotoxicity
- Trial name
- NCT00884767
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- France
- Volunteers
- 206 people
- Sponsor
- Institut Cancerologie de l'Ouest
Chemotherapeutic Agent Toxicity, Lung Cancer
Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to find the highest tolerable dose of Anvirzel (Nerium Oleander) that can be given to lung cancer patients receiving standard therapy with carboplatin and docetaxel.
- Trial name
- NCT01562301
- Testing
- Carboplatin, Docetaxel, Anvirzel
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Chemotherapeutic Agent Toxicity
Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer
RATIONALE: Nicotine patches may reduce hand-foot syndrome in patients receiving capecitabine for metastatic breast cancer. It is not yet known which nicotine patch regimen may be more effective in reducing hand-foot syndrome.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Palmar-plantar Erythrodysesthesia
- Trial name
- NCT00751101
- Testing
- Nicotine patch
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Francisco
Cardiac Toxicity, Chemotherapeutic Agent Toxicity
Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.
- Conditions
- Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Lymphoma
- Trial name
- NCT00577798
- Testing
- contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Breast Cancer, Paclitaxel Adverse Reaction
Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.
This study looks into how a common breast cancer treatment, paclitaxel, can sometimes cause severe side effects that make it hard for patients to continue treatment.
- Conditions
- Breast Cancer, Paclitaxel Adverse Reaction, Chemotherapeutic Toxicity, Chemotherapeutic Agent Toxicity
- Trial name
- PABTOX (NCT06387901)
- Testing
- Paclitaxel Chemotherapy
- Where
- 2 sites in Belgium
- Volunteers
- 40 people
- Sponsor
- Universitair Ziekenhuis Brussel
Cardiac Toxicity, Antitumor Drugs
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
According to the existing clinical data in our hospital, retrospective study was conducted to screen the risk factors with predictive value for TRC(trastuzumab-related cardiotoxicity) risk, and to construct the risk prediction…
- Conditions
- Cardiac Toxicity, Antitumor Drugs, Breast Cancer
- Trial name
- NCT04962425
- Testing
- Trastuzumab
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Peking University Third Hospital
Brest Cancer, Abemaciclib
Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)
Overall survival at 8 years under treatment for localized hormone-dependent breast cancer is 93.3% (1). Adjuvant therapy, especially hormone therapy, helps reduce the risk of recurrence.
- Conditions
- Brest Cancer, Abemaciclib, Adjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols
- Trial name
- MONARCHE29 (NCT06621459)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Brest
Ventricular Dysfunction, Cardiotoxicity
Optimising Screening for the Cardiotoxic Effects of Cancer Therapy
Cancer is a major worldwide health problem, with around 330.000 new annual cases only in the UK. Improved survival rates due to better treatments have lead to an increase in the prevalence of chemotherapy related cardiac disease…
- Conditions
- Ventricular Dysfunction, Cardiotoxicity, Chemotherapeutic Toxicity
- Trial name
- NCT06817044
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- Barts & The London NHS Trust
Herpes Simplex
Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia
RATIONALE: Acyclovir may be effective in preventing herpes simplex virus infection in patients with neutropenia. PURPOSE: This randomized phase III trial is studying the side effects of acyclovir and is comparing two doses of…
- Trial name
- NCT00855309
- Testing
- acyclovir sodium
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Wake Forest University Health Sciences
Chemotherapeutic Agent Toxicity, Colorectal Cancer
Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
RATIONALE: Calcium aluminosilicate anti-diarrheal (CASAD) may help treat and prevent diarrhea caused by irinotecan. It is not yet known whether CASAD is more effective than a placebo in treating and preventing diarrhea in…
- Conditions
- Chemotherapeutic Agent Toxicity, Colorectal Cancer, Diarrhea
- Trial name
- NCT00748215
- Testing
- calcium aluminosilicate anti-diarrheal
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Chemotherapeutic Agent Toxicity, Multiple Myeloma
Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib
This randomized phase II trial studies glutamine in preventing peripheral neuropathy in patients with multiple myeloma who are receiving bortezomib.
- Conditions
- Chemotherapeutic Agent Toxicity, Multiple Myeloma, Peripheral Neuropathy
- Trial name
- NCT01783522
- Testing
- glutamine, quality-of-life assessment
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Beth Faiman
Chemotherapy-Related Cognitive Impairment, Chemotherapeutic Toxicity
Investigating Cognitive Impairment in Young Patients With Cancer Prospectively
The MyBrain study investigates the brain function of children, adolescents and young adults during and after chemo treatment for cancer.
- Conditions
- Chemotherapy-Related Cognitive Impairment, Chemotherapeutic Toxicity, Chemo-brain, Cancer
- Trial name
- MyBrain (NCT05840575)
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Chemotherapeutic Agent Toxicity, Infection
Using Whole-Person-Care Guide in Patients Receiving Care for Cancer or Complications From Cancer Treatment
RATIONALE: Gathering information about patients with cancer and cancer-related conditions may help doctors learn more about a patient's needs and help doctors plan the best treatment.
- Conditions
- Chemotherapeutic Agent Toxicity, Infection, Malnutrition, Musculoskeletal Complications
- Trial name
- NCT00608738
- Testing
- informational intervention, medical chart review, questionnaire administration
- Volunteers
- 750 people
- Sponsor
- Northwestern University
Breast Cancer, Chemotherapeutic Agent Toxicity
G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer
RATIONALE: G-CSF may prevent or reduce febrile neutropenia in women receiving chemotherapy for breast cancer. It is not yet known which G-CSF regimen is more effective in preventing neutropenia.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Neutropenia
- Trial name
- NCT00771433
- Testing
- filgrastim
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Francois Baclesse
Breast Neoplasms, HER2/Neu Positive
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
This phase II trial studies the side effects and how well lapatinib ditosylate and trastuzumab work in treating older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has spread from where…
- Conditions
- Breast Neoplasms, HER2/Neu Positive, Geriatric Health Services
- Trial name
- NCT01273610
- Testing
- Lapatinib, Trastuzumab, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Cardiotoxicity
Understanding CARdiac Events in Breast Cancer
In Ireland, over 3,000 patients are diagnosed with breast cancer annually, and 1 in 9 Irish women will be diagnosed with breast cancer in their lifetime.
- Conditions
- Breast Cancer, Cardiotoxicity, Cardiomyopathies, Chemotherapeutic Toxicity
- Trial name
- UCARE (NCT05921279)
- Where
- 4 sites in Ireland
- Volunteers
- 100 people
- Sponsor
- National University of Ireland, Galway, Ireland
Chemotherapeutic Agent Toxicity, Pain
Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel
RATIONALE: Cryotherapy may help prevent peripheral neuropathy or nail toxicity in patients receiving chemotherapy. PURPOSE: This clinical trial studies cryotherapy in preventing peripheral neuropathy and nail toxicity in patients…
- Conditions
- Chemotherapeutic Agent Toxicity, Pain, Peripheral Neuropathy, Recurrent Breast Cancer
- Trial name
- NCT01243541
- Testing
- cryotherapy, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Northwestern University